Ranolazine

Generic Name: Ranolazine

Brand Names: Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₃N_₃O_₄

CAS Number: 95635-55-5

Unique Ingredient Identifier: A6IEZ5M406

Background: Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.

Indication: Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.

Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.

Associated Conditions: Chronic Angina, Ventricular Arrhythmia

Clinical Trials

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

Phase 2

Terminated

Conditions: Diarrhea Predominant Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2014-09-15

Last Posted Date: 2016-03-15

Lead Sponsor: Mayo Clinic

Target Recruit Count: 5

Registration Number: NCT02239926

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 4

Terminated

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2014-06-05

Last Posted Date: 2017-02-10

Lead Sponsor: Horizons International Peripheral Group

Target Recruit Count: 4

Registration Number: NCT02156336

Locations: 🇺🇸
Cardiovascular Institute of the South, Lafayette, Louisiana, United States
🇺🇸
Cardiology Associates, Fairhope, Alabama, United States

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

Phase 2

Terminated

Conditions: Angina

Interventions: Drug: Sugar pill
Drug: Ranolazine

First Posted Date: 2014-05-28

Last Posted Date: 2019-06-11

Lead Sponsor: North Florida Foundation for Research and Education

Target Recruit Count: 5

Registration Number: NCT02147834

Locations: 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

Phase 2

Completed

Conditions: Microvascular Angina

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2014-05-26

Last Posted Date: 2019-05-21

Lead Sponsor: Emory University

Target Recruit Count: 26

Registration Number: NCT02147067

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Phase 4

Completed

Conditions: Pulmonary Hypertension
Diastolic Left Ventricular Dysfunction

Interventions: Drug: Ranolazine

First Posted Date: 2014-05-08

Last Posted Date: 2017-05-17

Lead Sponsor: Boston University

Target Recruit Count: 10

Registration Number: NCT02133352

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy

Phase 2

Completed

Conditions: Dilated Cardiomyopathy

Interventions: Drug: Ranolazine

First Posted Date: 2014-05-08

Last Posted Date: 2021-04-28

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 10

Registration Number: NCT02133911

Locations: 🇸🇮
Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia

Ranolazine and Microvascular Angina by PET in the Emergency Department

Phase 4

Completed

Conditions: Microvascular Angina

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2014-01-31

Last Posted Date: 2017-05-16

Lead Sponsor: Yale University

Target Recruit Count: 31

Registration Number: NCT02052011

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Study to Reduce Symptoms of Premature Beats With Ranolazine

Phase 4

Conditions: Premature Ventricular Beats

Interventions: Drug: Ranolazine

First Posted Date: 2013-11-27

Last Posted Date: 2015-05-01

Lead Sponsor: Walter Reed National Military Medical Center

Target Recruit Count: 72

Registration Number: NCT01996618

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

Not Applicable

Completed

Conditions: Soft Tissue Metastases
Stage IV Prostate Cancer
Stage IIA Prostate Cancer
Stage III Prostate Cancer
Adenocarcinoma of the Prostate
Stage IIB Prostate Cancer
Bone Metastases